Scemblix (asciminib)

pCPA File Number: 21956
Negotiation Status:
Under consideration for negotiation
Indication(s):
For the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) previously treated with two or more tyrosine kinase inhibitors
Sponsor/Manufacturer:
Novartis Pharmaceuticals Canada Inc.
CADTH Project Number:
PC0275
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable